Ģ����Ƶ

Ģ����Ƶ’s ability to adapt has been��evident��throughout the COVID-19 pandemic, as it shifted from becoming an epicenter from COVID-19 patient care, to becoming��a site for Stage III clinical trials for a COVID-19 vaccine.��

During����of a clinical trial, researchers work with between 300 and 3,000 volunteers to test the efficacy of the��potential��vaccine and monitor patients for possible��adverse reactions.��Although this phase of study typically takes between one and four years to complete,��U.S.����has called on researchers “to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics”��with no compromise to patient safety.����

Patients interested in volunteering to participate in a clinical study may contact the����or email��cctucovid@med.cornell.edu.��

Recorded on August 20, 2020,�� this episode of the Ģ����Ƶ Insights webinar series, called “COVID Clinical Trials: Antibodies, Immunity, and Vaccine Development,”��brings together expert faculty members who have been on forefront of the medical center’s vaccine trials.��

To learn more about Ģ����Ƶ’s work in this area and the activities of our faculty, please visit these links:

• Learn more about Dr. Kristen Marks and her leading of the team conducting��. NewYork-Presbyterian/Weill Cornell Medical Center is one of dozens of medical centers around the U.S. where this still-experimental vaccine will be tested.��
• Dr. Roy Gulick is co-chairing a National Institutes of Health panel that is developing treatment guidelines for��COVID-19. Learn more about his and other Weill Cornell physician-scientists’��COVID��research in the summer 2020 issue of��.
• Dr. Carl Nathan, one of the world’s leading authorities on infectious diseases and advancing therapeutics from the bench to the bedside, is leading efforts to fight another looming health crisis:��.
• Dr. Marshall Glesby explains how��clinical��trials��work in a fascinating article in����newspaper.